MTOR and breast carcinoma: In addition, we tested 6 different MAPK pathway addicted cell lines: HCC827 and H3255 (EGFR mutant lung cancer), H2228 and H3122 (EML4-ALK translocated lung cancer, in which EGFRi was replaced with ALK inhibitor crizotinib in the 4D combination), DiFi and Lim1215 (EGFR dependent colorectal cancer) and in 2 different PI3K pathway addicted cell lines: SKBR3 and HCC1954 (HER2 amplified breast cancer, in which 4D combination consisted of HER2, PI3K, AKT and mTOR inhibitors).